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ABSTRACT
The systemic treatment of the bladder cancer is challenging. It is so due to moderate efficacy of chemotherapy 
and because of the restrictions secondary to the patient’s general performance status as well as an inadequate 
organ function (mainly renal function). The standards of the first line systemic treatment are established. The 
chemotherapy regimens containing platine derivates (preferably cisplatine) such as PG or MVAC are administered 
routinely. However such standard regarding the second line of systemic treatment is not defined. this reflects the 
lack of reliable scientific evidence supporting the chemotherapy use at this stage of the disease. Among several 
drugs being considered as the second line chemotherapy it is only vinflunine that proved its activity in phase III 
clinical trial and compared to the best supportive care improves prognosis and positively influence the quality of life. 
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Epidemiology
The bladder cancer, as the second most frequent 
genitourinary cancer, is mainly recognised in elderly 
people (at age between 60 and 70 years), and the aver-
age age at diagnosis is 70 years. It is about 3–4 times 
more frequent in men than in women. In 2011 there 
were 4700 new cases in Poland diagnosed in men and 
1300 in women. In 2012, 2400 men and 650 women died 
of bladder cancer in Poland [1]. 
The infiltration of the muscle layer of the bladder 
is recognised in about 25% of cases of bladder cancer. 
Over 90% of all bladder cancers are develop from the 
urothelium (carcinoma urotheliale).
The five-year survival in patients with bladder cancer 
in Europe is 68% (in Poland — about 62%) [1], while 
only 15% of patients with metastatic disease survive 
for five years.
Adjuvant chemotherapy
Patients with locally advanced bladder cancer and 
cT2-4a cN0M0 tumours, who are in good performance 
status (ECOG ≤ 1), should undergo preoperative 
cisplatin-based chemotherapy as it increases the rate 
of five-year survival by 5–8%. In patients who have un-
dergone primary radical surgery (cystectomy) and are 
diagnosed with ≥ T3 tumours or with regional lymph 
node involvement, adjuvant chemotherapy with cisplatin 
may be considered [2].
Palliative chemotherapy
Despite the aggressive radical treatment about half 
of the cystectomised patients have recurrent disease. 
In the majority of cases it is a distant recurrence, and 
only in about 10–30% of patients is local recurrence 
diagnosed. In patients with distant metastatic lesions or 
unresectable local recurrence systemic treatment with 
chemotherapy should be considered. The prognosis of 
patients who undergo the chemotherapy depends on 
the presence of unfavourable prognostic factors such as 
low performance status (Karnofsky score < 80%) and 
distant metastases [3]. The choice of the chemotherapy 
regimen depends on several factors (i.e. comorbidities 
and general performance status). Cisplatin, as the drug 
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of choice with proved activity in the first line treat-
ment of the bladder cancer, has substantial toxicity 
(nephrotoxicity, neurotoxicity, and myelotoxicity). For 
this reason, and taking into consideration the typical 
profile of patient with bladder cancer (elderly, usually 
with coexisting impaired renal function, circulatory 
insufficiency related to — for example — long-term 
nicotine addiction), less active regimens with carbopl-
atin or without platinum derivatives are administered. 
In the case of patients in pure performance status with 
the presence of distant metastatic spread the efficacy of 
the systemic treatment is minimal and its tolerance is 
usually bad. The standard of care in such cases is best 
supportive care only. 
First-line chemotherapy
The combination regimens of cisplatin and gem-
citabine (GC regimen) or methotrexate, vinblastine, 
doxorubicin, and cisplatin (M-VAC regimen) are 
most frequently used as the first line of palliative 
chemotherapy for bladder cancer. The GC regimen 
is usually used as the chemotherapy of choice in the 
first-line palliative treatment of advanced/metastatic 
bladder cancer due to its relatively favourable toxicity 
profile when compared to a classic M-VAC regimen 
while preserving the clinical efficacy with no differences 
between the two regimens [in terms of overall survival 
(OS); progression-free survival (PFS)] [4]. However, it 
has been proven that modification of classic M-VAC 
regimen, called HD-MVAC regimen, being adminis-
tered every 14 days with the support of granulopoietins 
is significantly more effective (objective response rate 
— 72% vs. 58%; OS — decrease in relative risk of death 
by 24%; PFS — decrease in relative risk of progression 
by 27%) than classic M-VAC and significantly less toxic 
[3]. Although the direct comparison of HD-MVAC and 
GC regimens is not available the first seems to be the 
treatment of choice in patients in good performance 
status and with high tumour burden.  
In patients with impaired renal function carboplatin 
is used instead of cisplatin; however, it must be empha-
sised that equal efficacy of the two drugs has not been 
proven [6]. Some patients who cannot be treated with 
platinum derivatives may benefit from gemcitabine 
monotherapy or a combination of paclitaxel and gem-
citabine. 
Second-line chemotherapy
The relevance of use as well as the inclusion criteria 
and the administration of second-line chemotherapy 
for bladder cancer are controversial. Taking into ac-
count the patient’s performance status, restricted organ 
function, long-term adverse events, and toxicity of the 
first-line chemotherapy as well as the relatively low 
chemo-sensitivity of bladder cancer cells, the use of 
second-line systemic treatment seems to be unreason-
able in the majority of patients, and in such cases the 
introduction of complex best supportive care is the 
treatment of choice. However, in some patients the 
good performance status allows consideration of use of 
systemic treatment of the second line. Due to restricted 
clinical data with high level of creditability the recom-
mended standard of care in patients who have failed to 
benefit from the first line of the systemic treatment does 
not exist. In its 2015 guidelines the National Compre-
hensive Cancer Network (NCCN) recommend referral 
of patients to clinical trials with use of novel drugs or 
therapeutic strategies [7]. According to international 
recommendations (i.e. NCCN or European Association 
of Urology — EAU) monotherapy with several cytotoxic 
drugs may be considered (taxanes/taxoids, gemcitabine, 
cisplatin, carboplatin, doxorubicin, ifosphamide, metho-
trexate, pemetrexed, or vinblastine) [7, 8]. There are no 
data to support the positive impact of the drugs men-
tioned above on the prognosis of patients undergoing 
second-line chemotherapy. The available data — from 
phase II clinical trials on small populations of patients 
with bladder cancer (usually < 40 patients) — indicate 
a small objective response rate (usually less than 20%) 
(Table 1). Vinflunine (VFL), as the representative of 
novel generation microtubule polymerisation inhibitors, 
is the only drug approved for second-line chemotherapy 
of patients with advanced bladder cancer. The drug has 
higher in vitro anti-cancer activity when compared to 
classic vinca alkaloids and has lower affinity to microtu-
bules than vinca alkaloids, which allows a lower neuro-
toxic effect of VFL [9]. In a phase III trial in a population 
of 370 patients with advanced bladder cancer and with 
failure of first-line cisplatin-containing chemotherapy, 
vinflunine with best supportive care (BSC) was com-
pared to BSC alone [10, 11]. The primary end-point was 
the difference in OS. After 45 months of follow-up — in 
per-protocol-population (about 5% of patients enrolled 
to the trial had an unproven disease progression on the 
first line chemotherapy) — a significant improvement 
of OS was shown in the study drug group. Median OS 
was 6.9 months versus 4.3 months, respectively, in the 
VFL + BSC and BSC arm (the relative risk of death 
decreased by 22%) [11]. The objective responses were 
observed only in patients in the VFL + BSC arm 
(8.6%) [10]. The stable disease was observed in 46.5% 
of patients (VFL + BSC) and 27.1% of patients (BSC). 
The difference in PFS medians (3.0 months versus 
1.5 months) favouring VFL was statistically significant. 
The use of active systemic treatment in patients with 
advanced bladder cancer after first-line chemotherapy 
failure is related to adverse events that are usually more 
intensive when compared to their intensity observed 
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during previous therapy. The common grade 3/4 adverse 
events related to VFL and observed in > 4% of patients 
were: neutropaenia (50% of patients), anaemia (19%), 
constipation (16%), and thrombocytopaenia (6%). The 
quality-of-life analysis, as one of the crucial elements 
of the trial and based on detailed assessment with 
European Organisation for Research and Treatment 
of Cancer — Quality of Life Questionnaires (EORTC 
QLQ) C30, revealed that VFL does not negatively 
influence the quality of life as compared to supportive 
care. Despite the continuous and gradual decrease of 
quality of life observed in the control arm, in the study 
drug group (VFL + BSC) the quality of life parameters 
improved after 18 weeks of treatment [10]. The active 
treatment decreased the proportion of patients requiring 
palliative radiotherapy (4% vs. 24%) and delayed the 
need for the introduction of other palliative procedures 
(5% vs. 26% during six months of follow-up). 
In 2015 the therapeutic procedures currently used 
in Poland in patients with advanced bladder cancer af-
ter first-line chemotherapy failure were reviewed. The 
analysis based on the data from 12 reference cancer 
centres in Poland revealed that about half of the patients 
receive second-line chemotherapy and the rest of this 
population receive supportive care only (i.e. analgesics, 
anticoagulants/prophylaxis of thromboembolic events, 
as well as antibiotics or blood products). Surprisingly, 
despite well-defined international guidelines, chemo-
therapy was mainly based on combined regimens con-
sisting of two drugs (gemcitabine + cisplatin or gemcit-
abine + paclitaxel) and more seldom on monotherapy 
with paclitaxel or gemcitabine.
Summary
The decision regarding the choice of second-line 
palliative treatment in patients with advanced bladder 
cancer should always take into account the patient’s gen-
eral performance status, assessment of organ function 
(especially kidneys), the efficacy and toxicity of previous 
systemic therapy, and the achieved time to disease pro-
gression. In patients with very good performance status 
and adequate renal function, who tolerated the first-line 
cisplatin-based treatment well and achieved long-lasting 
responses (longer than six months), re-challenge with 
previously used drugs may be considered [12]. However, 
such population is rarely observed in clinical practice, 
and in the majority of patients contraindications for 
platinum-derivatives used are present (pure perfor-
mance status, impaired renal function, audiometric defi-
cits, signs of grade ≥ 2 peripheral neuropathy, or grade 
3 cardiac insufficiency according to New York Heart 
Association (NYHA) classification) [6, 11]. For these 
reasons the use of drugs other than platinum-derivative 
cytotoxic medications for the second-line treatment 
should be considered in daily clinical practice. Among 
them only VFL has highly credible data available that 
supports the activity of this mitotic spindle inhibitor 
in palliative systemic treatment — favourable impact 
on prognosis (OS) and quality of life in patients with 
advanced bladder cancer after failure of the first line 
palliative chemotherapy.   
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